Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Recruitment Status

Active, not recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10531
Shown on this page
12
Current sort
Recently updated
Status scope
Active, not recruiting
Additional filters apply within this recruitment status.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this status page

These controls apply only within Active, not recruiting. Default order is Recently updated. Add condition, location, sponsor, or therapy filters to narrow this status page further.

Reset status filters
Clear filters
Showing 781–792 of 10,531 matching trials with status Active, not recruiting.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Supporting Health in Veterans With Heart Failure

NCT05839067
View directory record Official record
Conditions
Heart Failure
Interventions
Care-HF
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
4
States / cities
Gainesville, Florida • Togus, Maine • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 12, 2026, 12:16 AM EST
Active, not recruiting Phase 2 Interventional

Single Fraction or Multi-fraction Palliative Radiation Therapy for the Improvement of Quality of Life in Patients With Metastatic Gynecologic Cancers

NCT04516135
View directory record Official record
Conditions
Metastatic Malignant Female Reproductive System Neoplasm
Interventions
3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Volume Modulated Arc Therapy
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
3
States / cities
Camden, New Jersey • Columbus, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 12, 2026, 12:16 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Vascular Aging and Lp299v Study in Healthy Adults

NCT05296395
View directory record Official record
Conditions
Vascular Aging
Interventions
Lactobacillus Plantarum 299v in fermented oat drink, Heat-Killed Placebo control fermented drink
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
50 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 12, 2026, 12:16 AM EST
Active, not recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Sacituzumab tirumotecan, Pemetrexed, Carboplatin, H1 Receptor Antagonist, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
17
States / cities
Oakland, California • Roseville, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 12, 2026, 12:16 AM EST
Active, not recruiting Phase 3 Interventional

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

NCT04130997
View directory record Official record
Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
Ublituximab
Biological
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
19
States / cities
Pasadena, California • Denver, Colorado • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 12, 2026, 12:16 AM EST
Active, not recruiting Not applicable Interventional

Assessing the Use of Wearable Activity Trackers in a Pregnancy Cohort

NCT07331909
View directory record Official record
Conditions
Pregnancy Related
Interventions
Wearable Activity Tracker
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 12, 2026, 12:16 AM EST
Active, not recruiting Not applicable Interventional

Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring

NCT05587972
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Multiple Myeloma
Interventions
survey
Other
Lead sponsor
Carevive Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 12, 2026, 12:16 AM EST
Active, not recruiting Phase 2 Interventional

TheraSphere With Durvalumab and Tremelimumab for HCC

NCT05063565
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 12, 2026, 12:16 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

NCT06551324
View directory record Official record
Conditions
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Interventions
PF-06821497, Docetaxel, Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
70
States / cities
Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 12, 2026, 12:16 AM EST
Active, not recruiting Phase 2 Interventional Results available

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

NCT03047135
View directory record Official record
Conditions
Prostate
Interventions
Olaparib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Omaha, Nebraska • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 12, 2026, 12:16 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Aimmune Longitudinal Collaboration Study

NCT07218640
View directory record Official record
Conditions
Stool Spore Colony Forming Units, Microbiome Composition, Dietary Fiber, Stress
Interventions
Chia seeds
Other
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Ambler, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 12, 2026, 12:16 AM EST
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

NCT07425821
View directory record Official record
Conditions
Marburg Virus Disease
Interventions
rVSV∆G-MARV-GP, Placebo
Biological · Other
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 12, 2026, 12:16 AM EST